Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients-Reference-Cited by-同舟云学术

Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients

Published:2008-06 Issue:6 Volume:6 Page:701-706
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Bain Vincent G.,Kaita Kelly D.,Marotta Paul,Yoshida Eric M.,Swain Mark G.,Bailey Robert J.,Patel Keyur,Cronin Patrick W.,Pulkstenis Erik,McHutchison John G.,Subramanian G. Mani

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference22 articles.

1. Global epidemiology of hepatitis C virus infection;Shepard;Lancet Infect Dis,2005

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C—a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

4. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

5. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3;Mangia;N Engl J Med,2005

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients;Journal of Medical Virology;2013-10-26

2. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner;Hepatology;2012-06-05

3. Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b;The Journal of Clinical Pharmacology;2012-04

4. Half-Life Extension by Fusion to Recombinant Albumin;Therapeutic Proteins;2012-02-06

5. Interferons as Therapeutic Agents for Infectious Diseases;Infectious Disease Clinics of North America;2011-12